| Primary |
| Growth Hormone Deficiency |
34.2% |
| Hypopituitarism |
21.4% |
| Drug Use For Unknown Indication |
4.4% |
| Body Height Below Normal |
4.1% |
| Growth Retardation |
3.8% |
| Hypothyroidism |
3.7% |
| Hypertension |
3.4% |
| Dwarfism |
3.0% |
| Turner's Syndrome |
3.0% |
| Pituitary Tumour |
2.8% |
| Adrenal Insufficiency |
2.6% |
| Hypothalamo-pituitary Disorder |
2.5% |
| Hormone Replacement Therapy |
2.0% |
| Blood Growth Hormone |
1.4% |
| Depression |
1.4% |
| Blood Growth Hormone Decreased |
1.3% |
| Pain |
1.3% |
| Immunosuppressant Drug Therapy |
1.2% |
| Prophylaxis |
1.2% |
| Secondary Hypothyroidism |
1.2% |
|
| Hospitalisation |
14.9% |
| Pharmaceutical Product Complaint |
8.8% |
| Vomiting |
6.9% |
| Weight Increased |
6.4% |
| Epiphysiolysis |
5.9% |
| Death |
5.6% |
| Weight Decreased |
5.3% |
| Visual Acuity Reduced |
5.1% |
| Pituitary Tumour Recurrent |
4.0% |
| Pneumonia |
4.0% |
| Convulsion |
3.7% |
| Obstructive Airways Disorder |
3.7% |
| Brain Neoplasm |
3.5% |
| Loss Of Consciousness |
3.5% |
| Pituitary Tumour Benign |
3.5% |
| Drug Dose Omission |
3.2% |
| No Adverse Event |
3.2% |
| Surgery |
3.2% |
| Neoplasm |
2.9% |
| Neoplasm Recurrence |
2.9% |
|
| Secondary |
| Growth Hormone Deficiency |
34.1% |
| Hypopituitarism |
17.1% |
| Drug Use For Unknown Indication |
4.7% |
| Adrenal Insufficiency |
4.1% |
| Hypothyroidism |
3.7% |
| Hypertension |
3.5% |
| Cardiac Failure Congestive |
3.1% |
| Growth Retardation |
3.1% |
| Insomnia |
3.1% |
| Dwarfism |
2.9% |
| Osteoporosis |
2.7% |
| Product Used For Unknown Indication |
2.5% |
| Essential Hypertension |
2.3% |
| Hypogonadism |
2.3% |
| Secondary Hypothyroidism |
2.3% |
| Type 2 Diabetes Mellitus |
2.3% |
| Immunosuppressant Drug Therapy |
1.7% |
| Hypercholesterolaemia |
1.6% |
| Hyperuricaemia |
1.6% |
| Hyperlipidaemia |
1.4% |
|
| Weight Increased |
15.8% |
| Epiphysiolysis |
7.9% |
| Vomiting |
7.9% |
| Oesophageal Carcinoma |
6.5% |
| Visual Acuity Reduced |
5.8% |
| White Blood Cell Count Increased |
5.8% |
| Pituitary Tumour Benign |
5.0% |
| Scoliosis |
4.3% |
| Testicular Pain |
4.3% |
| Weight Decreased |
4.3% |
| Hepatic Adenoma |
3.6% |
| No Adverse Event |
3.6% |
| Paraesthesia |
3.6% |
| Stomach Discomfort |
3.6% |
| Visual Impairment |
3.6% |
| Fatigue |
2.9% |
| Hospitalisation |
2.9% |
| Incorrect Dose Administered |
2.9% |
| Off Label Use |
2.9% |
| Pain |
2.9% |
|
| Concomitant |
| Drug Use For Unknown Indication |
31.4% |
| Product Used For Unknown Indication |
15.2% |
| Diabetes Mellitus |
7.6% |
| Growth Hormone Deficiency |
4.8% |
| Hypopituitarism |
4.8% |
| Diabetes Mellitus Non-insulin-dependent |
3.8% |
| Attention Deficit/hyperactivity Disorder |
2.9% |
| Body Height Below Normal |
2.9% |
| Crohn's Disease |
2.9% |
| Fibromyalgia |
2.9% |
| Psoriatic Arthropathy |
2.9% |
| Type 2 Diabetes Mellitus |
2.9% |
| Blood Growth Hormone Abnormal |
1.9% |
| Blood Triglycerides Increased |
1.9% |
| Bone Pain |
1.9% |
| Breakthrough Pain |
1.9% |
| Computerised Tomogram Abdomen |
1.9% |
| High Density Lipoprotein Decreased |
1.9% |
| Obesity |
1.9% |
| Pain |
1.9% |
|
| Vomiting |
13.8% |
| Migraine |
6.9% |
| Nausea |
6.9% |
| Rash Maculo-papular |
6.9% |
| Throat Irritation |
6.9% |
| Toothache |
6.9% |
| Urticaria |
6.9% |
| Astrocytoma |
3.4% |
| Chest Pain |
3.4% |
| Chronic Myelomonocytic Leukaemia |
3.4% |
| Decreased Appetite |
3.4% |
| Diarrhoea |
3.4% |
| Drug Effect Decreased |
3.4% |
| Dry Skin |
3.4% |
| Epistaxis |
3.4% |
| Injection Site Haematoma |
3.4% |
| Injection Site Pain |
3.4% |
| Injection Site Pruritus |
3.4% |
| Irritability |
3.4% |
| Left Ventricular Hypertrophy |
3.4% |
|
